Current Treatment Options in CLL Moritz Bewarder, Stephan Stilgenbauer, Lorenz Thurner, and Dominic Kaddu-Mulindwa

[Tupelomojo]

Abstract

Simple Summary

Standard treatment for chronic lymphocytic leukemia (CLL) has experienced a dramatic change over the last years. Until recently, CLL was treated using chemotherapy in combination with anti-CD20 antibody-based immunotherapy. Depending on age and clinical condition, patients received more or less intensive chemotherapy and were at risk of side effects commonly associated with chemotherapy. Currently, patients are mostly treated with so-called novel agents, including BTK inhibitors, Bcl-2 inhibitors and PI3K inhibitors, which are generally well tolerated but have a specific side effect profile.

More @ ncbi.nlm.nih.gov/pmc/articl...

[bennevisplace]

Thanks, this is a fairly recent review of the existing treatment landscape for CLL with summary results of the relevant clinical trials. As such a useful source.

[Tupelomojo in reply to bennevisplace]

Thanks, I will continue to provide the most recent CLL material that I can find.

[Smakwater]

Great find to summarize and overview the CLL treatment landscape.

JM

[Tupelomojo in reply to Smakwater]

Smakwater, your appreciation is appreciated with utmost appreciation

🤪 (Thanks 👍)